Filing Analysis
Filana Therapeutics reported the results of its 2026 Annual Meeting of Stockholders held on June 11, 2026. Key outcomes include the election of three directors, the ratification of Ernst & Young LLP as auditors, and the approval of Amendment No. 2 to the 2018 Omnibus Incentive Plan.
📋 Key Facts
- Stockholders approved Amendment No. 2 to the 2018 Omnibus Incentive Plan, increasing authorized shares from 5,000,000 to 9,000,000.
- The 2018 Plan term was extended by two years, now expiring January 31, 2030.
- The amendment explicitly prohibits the repricing, replacing, or cash-out of stock options/SARs without stockholder approval.
- Three directors (Richard J. Barry, Pierre Gravier, and Claude Nicaise, M.D.) were elected for three-year terms.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Quorum was established with 24,559,776 shares represented (approx. 51% of the 48,307,896 shares entitled to vote).
Filana Therapeutics, Inc. reported its financial results and operations for the period ending May 7, 2026. The disclosure was made via a press release furnished under Item 2.02 of Form 8-K.
📋 Key Facts
- Filana Therapeutics, Inc. (Ticker: FLNA) filed the 8-K on May 7, 2026.
- The filing specifically addresses Item 2.02: Results of Operations and Financial Condition.
- A press release dated May 7, 2026, was included as Exhibit 99.1.
- The information is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
On April 22, 2026, Michael O’Donnell notified Filana Therapeutics, Inc. of his resignation from the Board of Directors, effective at the conclusion of the 2026 annual meeting of stockholders. The company stated that the resignation was not the result of any disagreement regarding operations, policies, or practices.
📋 Key Facts
- Director Michael O’Donnell notified the Board of his resignation on April 22, 2026.
- The resignation is effective at the conclusion of the Company’s 2026 annual meeting of stockholders.
- The Company explicitly stated there were no disagreements with management or the Board.
- Mr. O’Donnell will continue to serve as a director until the resignation becomes effective.
Filana Therapeutics, Inc. furnished a press release on March 12, 2026, announcing its results of operations and financial condition.
📋 Key Facts
- The filing was made under Item 2.02: Results of Operations and Financial Condition.
- A press release dated March 12, 2026, was included as Exhibit 99.1.
- The company's common stock is registered on the NASDAQ Capital Market under the symbol FLNA.
Cassava Sciences, Inc. has officially changed its corporate name to Filana Therapeutics, Inc. and will change its Nasdaq ticker symbol from 'SAVA' to 'FLNA' effective March 11, 2026. The company also amended its bylaws to modernize governance provisions and updated its corporate website.
🚩 Red Flags
- Rebranding from 'Cassava Sciences' may be a strategic move to distance the entity from past high-profile controversies and regulatory scrutiny associated with the previous name.
📋 Key Facts
- Legal name change from Cassava Sciences, Inc. to Filana Therapeutics, Inc. effective March 10, 2026.
- Ticker symbol change from 'SAVA' to 'FLNA' on the Nasdaq Capital Market effective March 11, 2026.
- Corporate website updated to www.filanatx.com.
- Bylaws amended to clarify provisions regarding stockholder meetings, advance notice requirements, and director terms.
- The name change was effected via a Certificate of Amendment to the Restated Certificate of Incorporation filed in Delaware.
Cassava Sciences announced on February 19, 2026, that the U.S. Department of Justice Fraud Section has closed its inquiry into the company regarding allegations of research misconduct. The DOJ inquiry was related to a criminal case (United States v. Wang) that was dismissed with prejudice on October 23, 2025.
🚩 Red Flags
- Previous DOJ fraud investigation indicates past regulatory scrutiny over research misconduct allegations
- Research misconduct allegations could have impacted company credibility and clinical trial data integrity
📋 Key Facts
- DOJ Fraud Section closed previously-disclosed inquiry into Cassava Sciences regarding research misconduct allegations
- The inquiry was related to indictment in United States v. Wang, 8:24-cr-000211-TDC (D. Md.)
- The underlying criminal case was dismissed with prejudice by DOJ on October 23, 2025
- Company issued press release on February 19, 2026, announcing the closure
- Filing includes both Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events)